BioSpace News Archive

BostonGene today announced that four abstracts have been accepted for poster presentations and two abstracts have been accepted for online publication for the 2023 ASCO Annual Meeting (ASCO), which will be held June 2 – 6, 2023, at McCormick Place Convention Center in Chicago, IL.

Canadian life sciences company Ondine Biomedical has appointed Dr. Simon Sinclair as Chief Medical Officer, as the Company prepares to start the US Phase 3 trial of its nasal photodisinfection technology.

Dragonfly Therapeutics, Inc., announced it has expanded its clinical leadership team with the addition of Dr. Robin Edwards, previously Global Head of Translational Sciences at Daiichi Sankyo and Head of Translational at Bristol Myers Squibb, and Dr. David Ferry, previously Head of GI Oncology at Eli Lilly.

Quest Diagnostics Incorporated (NYSE: DGX), the world’s leading provider of diagnostic information services, announced that it is scheduled to speak at the William Blair 43rd Annual Growth Stock Conference.

Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 program comprising the REVISIT (NCT03329092) and ASSEMBLE (NCT03580044) studies evaluating the efficacy, safety, and tolerability of the novel investigational antibiotic combination aztreonam-avibactam.

Shasqi, Inc. (“Shasqi”), a clinical-stage biotech company, whose mission is to revolutionize cancer treatment with click chemistry, announced today it has entered into a research collaboration with Johnson & Johnson Enterprise Innovation Inc.

Compass Therapeutics, Inc. announced that the Company will participate in the following investor events during the month of June 2023.

GenEros Biopharma Ltd. (“GenEros” or “the Company”) will unveil the preliminary data from the phase I clinical trial of GEC255, a unique KRAS G12C inhibitor, at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

CoRegen announced today the publication of research, titled, “Steroid receptor coactivator 3 is a key modulator of regulatory T cell-mediated tumor evasion,” in the peer-reviewed journal Proceedings of the National Academy of Sciences (PNAS).

Bayer and Cedilla Therapeutics today announced an exclusive license agreement to develop and commercialize Cedilla Therapeutics’ CyclinE1/CDK2 complex inhibitors which selectively address oncogenic drivers.